Study to Evaluate the Safety of UF-KURE-BCMA CAR T-Cells in Advanced Myeloma (NCT07611149) | Clinical Trial Compass
Not Yet RecruitingPhase 1
Study to Evaluate the Safety of UF-KURE-BCMA CAR T-Cells in Advanced Myeloma
12 participantsStarted 2026-09-01
Plain-language summary
The goal of this study is to evaluate the safety of a new type of CAR T-cell, UF-KURE-BCMA, for the treatment of patients with advanced multiple myeloma that has not responded to other therapies. The main question is whether the use of these new CAR T-cells is safe for patients with this condition. Secondarily, the study will also look at the response of myeloma to this therapy.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Age: ≥18 years at time of signing informed consent
. Diagnosis: Documented multiple myeloma meeting one of the following:
. Prior Therapy:
. Measurable Disease: At least one of the following at screening (for response assessment eligibility):
. Performance Status: ECOG Performance Status 0-2 (see Appendix A)
. Organ Function: Adequate organ function as defined by:
. Prior Therapy Washout:
. Informed Consent: Ability to understand and willingness to provide written informed consent
Exclusion criteria
. Disease-Specific Exclusions:
. Malignancy Exclusions:
. Cardiovascular Exclusions:
. Infectious Disease Exclusions:
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Incidence of dose-limiting toxicities (DLT occurring within 28 days of CAR-T cell infusion)